Objective-Patients with elastin deficiency attributable to gene mutation (supravalvular aortic stenosis) or chromosomal microdeletion (Williams syndrome) are characterized by obstructive arteriopathy resulting from excessive smooth muscle cell (SMC) proliferation, mural expansion, and inadequate vessel size. We investigated whether rapamycin, an inhibitor of the cell growth regulator mammalian target of rapamycin (mTOR) and effective against other SMC proliferative disorders, is of therapeutic benefit in experimental models of elastin deficiency. Approach and Results-As previously reported, Eln −/− mice demonstrated SMC hyperplasia and severe stenosis of the aorta,
O bstructive arteriopathy is characteristic of patients with elastin deficiency caused by heterozygous mutation of the ELN gene in a disorder termed familial supravalvular aortic stenosis (SVAS; Online Mendelian Inheritance in Man [OMIM] No. 185500) or by partial deletion of chromosome 7 resulting in heterozygous loss of 26 to 28 genes, including an ELN allele, in a condition termed Williams syndrome (WS; OMIM No. 194050). 1 Although stenoses may occur in any medium-or large-sized artery, it typically affects the ascending thoracic aorta sparing its root that contains the aortic valvehence the term supravalvular. The obstructive lesions result from medial hypertrophy attributable to increased proliferation of smooth muscle cells (SMC) together with an increased number of thinner-than-normal elastic lamellae. 2 Lumen loss is exacerbated by underdevelopment of the affected vessels. This combination of pathological factors was described by Williams in his original description of the eponymous disease as "the obstruction was due in part to hypertrophy of the media just above the sinuses of Valsalva and in part to constriction of the aortic wall at the same level." 3 A targeted mutation of Eln in mice has recapitulated key features of SVAS and WS arteriopathy that varies according to gene dosage, that is, severe stenoses attributable to excessive SMC proliferation and markedly underdeveloped aortas in homozygous animals versus no focal obstruction but modestly smaller diameter aortas with increased number of thinner elastic lamellae in heterozygous animals. [4] [5] [6] The molecular mechanisms linking loss of elastin to excess SMC proliferation remain poorly understood. The impact of arterial disease in SVAS and WS is variable and ranges from life-threatening malperfusion problems in infants to asymptomatic lesions in elderly subjects, although many patients have modest-to-significant obstructive arterial lesions. 7 Current therapy for focal arterial obstruction in these patients includes surgical reconstruction often with prosthetic patches and, for certain indications, percutaneous balloon dilatation with or without stent placement. 1 However, there is currently no treatment for diffuse arterial lesions or to address the underlying abnormality of SMC hyperplasia in SVAS and WS.
Cellular proliferation is associated with activation of the mammalian target of rapamycin (mTOR) complex 1 that signals via downstream effectors, including p70-S6 kinase (S6K), ribosomal protein S6, and 4E-binding protein 1, to regulate protein translation and cell growth. 8 Pharmacological inhibitors of mTOR, such as rapamycin, have potent antiproliferative effects in addition to immunosuppressive properties. 9 In clinical trials, rapamycin-coated stents decrease intimal proliferation and restenosis in atherosclerotic coronary arteries, 10 and rapamycin reduces the incidence of intimal thickening in coronary arteries of rejecting cardiac allografts. 11 The therapeutic benefit of mTOR inhibitors in arteriosclerosis is ascribed to their potent antimitogenic effect. 12, 13 We hypothesized that inhibition of SMC proliferation by rapamycin will also prevent obstructive arteriopathy mediated by elastin deficiency, and we tested this strategy in experimental systems of SVAS and WS. 14, 15 
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Murine Models of Elastin-Deficient Aortopathy
To investigate pathogenetic mechanisms and therapeutic opportunities in SVAS and WS, we used an established murine model in which a targeted mutation of exon 1 disrupts the Eln allele. 4 As previously reported, 4-6 pups homozygous for loss of Eln died by 3 days of birth with severe stenosis of the thoracic aorta sparing its root ( Figure 1A) , whereas heterozygote animals survived long term characterized by modestly decreased aortic diameter ( Figure 1B) with an increased number of medial elastic lamellae ( Figure 1C ). Ultrastructural analysis of aortas from adult Eln haploinsufficient mice showed the elastic laminae to be thinner structures, whereas SMC morphology seemed normal ( Figure I in the online-only Data Supplement). Thus, newborn and mature animals offer different arteriopathy end points to assess depending on gene dosage.
Increased mTOR Signaling in Elastin-Deficient Aortas Is Inhibited by Rapamycin
We examined for dysregulation of mTOR signaling, because this pathway plays a crucial role in SMC proliferation in other obstructive arterial diseases. 10, 11 mTOR activity was evaluated by phosphorylation of an effector, S6K. In newborn pups, the expression of phospho-S6K was markedly increased in individual Eln −/− aortas, and a similar change of lesser magnitude was noted in Eln +/− aortas (Figure 2A ). We also pooled aortas from multiple newborn pups to obtain sufficient material to confirm increased activation of several other effectors of this signaling pathway, including mTOR, S6, and 4E-binding protein 1 ( Figure 2B ). Because aortic abnormalities are known to develop at E17.5 in this experimental model, 4 we reasoned that effective pharmacological treatment would require in utero delivery. Given that repeated fetal administration is extremely invasive, we pursued transplacental delivery of rapamycin. 16 We confirmed that maternal administration of rapamycin at 2 mg/kg IP daily during late gestation from E16.5 to E18.5 or 19.5 (treated pregnant mice often delivered at E19 and occasionally at E20) inhibited phospho-S6K expression in the aortas of neonates on the day of birth ( Figure 2C ). Further rapamycin administration to lactating mothers continued to suppress mTOR signaling in the aortas of offspring until weaning at 3 weeks postpartum ( Figure 2D ).
Rapamycin Reduces SMC Proliferation and Aortic Obstruction in Eln −/− Mice
To assess the effects of mTOR inhibition on the obstructive arterial phenotype, rapamycin was administered to gravid Eln +/− females (mated with Eln +/− males) for the last 3 days of pregnancy, and the pups were euthanized on the day of birth for vascular analyses. SMC proliferation was assessed by uptake of the synthetic nucleoside, bromodeoxyuridine administered to pregnant mice at E17.5, the time point at which medial hyperplasia attributable to elastin deficiency is known to occur. 4 As expected, aortas from Eln −/− and Eln +/− pups had more numerous bromodeoxyuridine-labeled medial cells than Eln +/+ littermates from vehicle-treated animals. Treatment with rapamycin significantly diminished SMC proliferation in the ascending aortas of all littermates, such that medial bromodeoxyuridine frequency was similar in Eln −/− , Eln +/− , and Eln +/+ pups ( Figure  3A ). Stenosis was assessed by the aortic lumen area filled with blood postmortem. Strikingly, rapamycin treatment markedly reduced the degree of ascending aorta and aortic arch obstruction in Eln −/− pups ( Figure 3B ). In further experiments in which the animals were not euthanized but monitored for survival, the mortality of Eln −/− pups from rapamycin-treated mice was indistinguishable from that of vehicle-treated controls despite the increase in aortic lumen area ( Figure 3C ).
Rapamycin Prevents Medial Hyperlamellation Without Compromising Aortic Size in Eln +/− Mice
We next tested the effects of mTOR inhibition on the more modest arterial phenotype resulting from Eln hemizygosity. To avoid inoculation of the delicate pups, rapamycin or vehicle was administered to their mothers from E16.5 of pregnancy and throughout lactation until weaning at P21. Anesthetized weanlings were examined by ultrasound. Rapamycin treatment decreased aortic diameter in Eln +/+ offspring, but did not further diminish the size of the smaller aorta in Eln +/− littermates ( Figure 4A ). Drug exposure resulted in somatic growth retardation that manifested as decreased body weight of all the animals ( Figure 4B ), a known effect of mTOR inhibition. 16 The mice were euthanized at 3 weeks of age, and their aortas were further analyzed by histology. The number of elastic lamellae in the ascending aorta of Eln +/+ mice remained unchanged, whereas the increased number of elastic lamellae in vehicletreated Eln +/− mice was rescued by rapamycin treatment ( Figure  4C ). Morphometric determinations of total vessel area of the aorta mirrored those measured by ultrasound (data not shown).
Changes in cross-sectional media area, a measure of medial mass, were also in parallel to those of aortic size ( Figure 4D ).
Prolonged mTOR Activation in Human SVAS and WS Cells
To determine whether our findings in murine models may be of relevance in human disease, we examined mTOR signaling and the effects of mTOR inhibition in cultured cells from patients with elastin haploinsufficiency. Specifically, we compared responses to platelet-derived growth factor (PDGF), one of the mitogens present in serum, in SMC propagated from the coronary arteries of a patient with SVAS and from the ascending aorta of a patient with WS versus control cells. We established that PDGF at 10 ng/mL was an appropriate near-maximal dose to use for comparisons ( Figure II in the online-only Data Supplement). At this dose, treatment with PDGF for 15 to 180 minutes stimulated mTOR signaling to a similar extent in serum-deprived SMC from patients with SVAS and WS versus controls ( Figure 5A ). Although early signaling events were comparable, we noted that the basal expression of phospho-S6K and phospho-S6 was consistently higher in SVAS and WS than control cells before treatment with PDGF (ie, 24 hours after serum withdrawal). Further time course experiments revealed a longer duration of PDGF-mediated mTOR signaling over 12 to 24 hours in elastin-deficient SMC ( Figure 5B ), although a paradoxical partial rebound in mTOR signaling was found in both patient and control cells after extended serum deprivation for 36 to 48 hours. Similarly, a prolonged duration of mTOR signaling was found in SVAS and WS cells after serum withdrawal ( Figure III in the online-only Data Supplement).
Rapamycin Inhibits mTOR Signaling and Proliferation of Human SVAS and WS Cells
Finally, we tested the effects of mTOR inhibition in our cultured SMC. The activation of mTOR effectors induced by 20% serum was abolished by rapamycin at a dose of 10 ng/mL ( Figure 6A and 6B). Rapamycin at 10 ng/mL also prevented mTOR signaling after serum withdrawal and treatment with PDGF ( Figure IV in the online-only Data Supplement). As previously reported, 2 growth curve analyses over 8 days demonstrated greater proliferation of SVAS and WS cells than control SMC in response to 20% serum. Rapamycin at 10 ng/mL markedly reduced serumdependent proliferation of both SVAS and WS cells, albeit to a lesser extent compared with control SMC (Figure 6C and 6D) . Higher doses of rapamycin up to 100 ng/mL were only modestly more effective in suppressing residual SMC proliferation and did not achieve complete growth quiescence. Rapamycin at 10 ng/ mL also greatly diminished the numbers of SMC treated with PDGF in the presence of low or optimal concentrations of serum, although effects on cell survival rather than on cell proliferation cannot be distinguished under the former conditions of serum depletion ( Figure IV in the online-only Data Supplement). The inhibitory effect of rapamycin on cell growth was likely independent of autophagy-mediated cell death, as induction of autophagy pathways in SMC was only seen at rapamycin doses many orders of magnitude higher than those required to suppress mTOR signaling and cellular proliferation ( Figure V in the online-only Data Supplement) corroborating previous similar findings in this cell type. 17 Moreover, rapamycin at the relevant in vitro concentrations of 1 to 100 ng/mL did not induce SMC death as assessed by cell membrane integrity ( Figure V in the onlineonly Data Supplement). To enhance our observations from only 2 patients with elastin deficiency and to determine whether the findings apply to cell types other than SMC, fibroblasts were obtained from the skin of an additional patient with WS. As previously reported, 2 WS fibroblasts proliferated faster than control cells during the log phase of growth. Similar to the effects on SMC, rapamycin also markedly reduced the proliferation of both WS and control fibroblasts ( Figure VI 
Discussion
We find that mTOR signaling in vessel wall cells is increased by genetic loss of elastin and that mTOR inhibition by rapamycin reduces SMC proliferation and aortic obstruction in elastin-deficient mice in vivo and decreases the excessive growth of cultured cells from patients with SVAS and WS in vitro. These results suggest that pharmacological therapy may be possible for generalized arteriopathy of patients with SVAS and WS in addition to the current mechanical means of treatment for focal lesions. Our data demonstrate an important role for mTOR signaling in medial hypertrophy resulting from elastin deficiency, although additional mitogenic pathways are not excluded. Similarly, mTOR activity is critical for the proliferation of SMC in arteriosclerosis. 10, 11 The antiarteriosclerotic effects of rapamycin include direct suppression of intimal and medial SMC proliferation independent of its immunosuppressive properties on leukocytes. 13 Of relevance, rapamycin has also been shown to inhibit SMC proliferation and medial thickening of the pulmonary artery induced by hypoxia in mice. 18 A direct relationship between loss of elastin and increased cellular proliferation has been previously reported for human and murine SMC. 2, 4 However, these studies did not describe molecular mechanisms by which elastin regulates cell division. In this initial report, we do not identify intermediaries leading from elastin deficiency to activation of the nutrient-sensing and growth factor-dependent mTOR pathway, nor do we uncover the basis for prolonged mTOR signaling in SVAS and WS cells.
Our current studies are examining the activity of upstream mediators and regulatory phosphatases. Although direct effects of elastin on mTOR signaling cannot be excluded, we speculate that indirect hemodynamic and arterial stress responses may also be involved. Elastin has a structural role in large arteries, and its genetic deficiency in mouse models is known to result in aortic stiffness and systemic hypertension 1, 6, 7 that is alleviated by reduction of nicotinamide adenine dinucleotide phosphate, reduced (NADPH)-oxidase activity. 19 However, cell intrinsic factors also play a role as both the current and previous studies demonstrate increased SMC proliferation in vitro independent of hemodynamic factors. 2, 4 A site-sensitivity of the vasculature is suggested by the preferential development of severe stenosis in the aorta rather than the pulmonary trunk starting at E17.5 when fetal blood pressure is equal in both systemic and pulmonary conduits at this stage. 4 Epigenetic factors are also suggested by the sparing of the aortic root whose SMC originate from cardiac precursors that differ from the origins of the remainder Figure 4 . Rapamycin prevents medial hyperlamellation without compromising aortic size in Eln +/− mice. Vehicle or rapamycin at 2 mg/kg was administered intraperitoneally daily to gravid Eln +/− mice from E16.5 to E18.5-E19.5, and maternal treatment was continued throughout lactation from P0 to P21. Eln +/+ , and Eln +/− weanlings were analyzed at 3 weeks of age. A, Representative ultrasound images of the distal ascending aorta diameter (blue lines) and the results from multiple animals are shown in the histograms (n=3-5; *P<0.05, t test). B, Body weight of the animals (n=3-5; *P<0.05, **P<0.01, t test). C, Representative elastin-Van Gieson histological stains of elastic lamellae (black appearance) in distal ascending aorta cross-sections (bar, 50 µm) and the number of layers from multiple mice are shown in the histograms (n=3-5; **P<0.01, Mann-Whitney test of rank transformed data). D, Media area (between internal and external elastic laminae) was calculated by morphometric evaluation of distal ascending aorta cross-sections (n=3-5; *P<0.05, t test).
of the thoracic aorta. 20 The higher proliferative rate of cultured dermal fibroblasts from patients with SVAS and WS in this and previous work 2 implies that the abnormal cellular phenotype is not restricted to elastin-producing vascular SMC and that adventitial fibroblasts may also play a role in elastin-deficient arteriopathy via paracrine signaling to the medial layer.
The more atypical arteriopathy manifestations resulting from elastin deficiency of increased elastic lamellae and vessel underdevelopment are not as well studied as stenosis and hypertension sequelae. An increased number of elastic lamellae in the aortic wall have been previously interpreted as secondary to the increased proliferation of SMC, but direct proof was lacking. 2 Our work with rapamycin shows that the medial hyperlamellation phenotype can be rescued by inhibiting SMC mitogenesis starting at late gestation. The relative sparing of aortic growth in Eln +/− mice by rapamycin is fortuitous because any gain in lumen size by suppressing medial hypertrophy may be lost by further inward vascular remodeling. We have previously observed that rapamycin allows outward vascular remodeling, while effectively inhibiting intimal and medial SMC proliferation in an experimental model of arteriosclerosis. 13 A similar sparing of coronary artery outward vascular remodeling by rapamycin is apparent in the data set from a clinical trial in patients who had cardiac transplant. 11 The reasons for this beneficial drug profile are unknown, but may pertain to rapamycin-insensitive mTOR complex 2 signaling, which regulates the cytoskeleton and spatial aspects of growth. 8 Figure 5 . Prolonged mammalian target of rapamycin (mTOR) signaling in smooth muscle cells (SMC) from patients with supravalvular aortic stenosis (SVAS) and Williams syndrome (WS). A, Representative western blotting for mTOR signaling effectors in serum-deprived SMC from the coronary arteries of a patient with SVAS (left) or from the ascending aorta of a patient with WS (right) and from corresponding vessels of age-matched controls in response to platelet-derived growth factor (PDGF)-BB at 10 ng/mL for 15 to 180 minutes. Phospho-p70-S6 kinase (S6K) and phospho-S6 normalized to β-actin are shown for the patient with SVAS (performed in duplicate) vs 4 controls (left) or for the patient with WS vs 3 controls (right). B, Similar analysis of PDGF-BB-mediated mTOR signaling for a longer duration of 6 to 48 hours in serum-deprived SMC from the patient with SVAS vs 4 controls (left) or from the patient with WS vs 3 controls (right).
Yet mTOR inhibition also failed, at least partially, in certain key end points of our study. Rapamycin did not completely suppress the division of cultured SMC from patients with SVAS and WS. Moreover, rapamycin did not completely relieve aortic obstruction nor did it prolong the survival of Eln −/− pups. We cannot exclude rapamycin toxicity contributing to the death of Eln −/− pups, although this is unlikely to occur within the observed time frame of a few days. Toxicity was not related to single allele deletion as equivalent growth retardation occurred in Eln +/− and Eln +/+ mice, which is of relevance to patients with elastin haploinsufficiency diseases. Explanations for the modest efficacy of rapamycin in the setting of elastin deficiency include inadequate drug dosage, mTOR-independent mitogenic pathways, or that death occurs from residual aortic obstruction and nonvascular causes, such as cardiac or respiratory failure. 21, 22 We did not measure drug levels in pups, but pregnant animals were administered doses of rapamycin known to be effective for transplacental delivery in mice. 16 The inhibition of aortic mTOR activity, the prevention of medial hyperlamellation, and somatic growth retardation all argue for successful dosing. It is possible that the concentration of rapamycin required to inhibit SMC proliferation may be higher than that for other effects. We have previously found that higher doses of rapamycin at 1.5 mg/kg per day were required to suppress SMC mitogenesis rather than 0.5 mg/kg per day for immunosuppressive effects on alloreactive T cells in the same humanized mouse model of graft arteriosclerosis. 13, 23 This observation is of concern for proposed trials in children with generalized arteriopathy because rapamycin can have serious side-effects in pediatric transplant recipients even at the dose used for immunosuppression. 24 Besides our study, somatic growth retardation by rapamycin has been observed in mouse embryos 16 and in young rats. 25 This phenomenon in children is controversial with one study finding adverse effects of rapamycin on growth of pediatric transplant recipients, 26 whereas another study found normal linear growth in a similar cohort. 27 On the other hand, similar doses of mTOR inhibitors seem to be better tolerated and not cause growth retardation in children without organ transplants or the concurrent use of multiple other immunosuppressive agents, for example, in the treatment of astrocytomas associated with tuberous sclerosis. 28 Before proceeding with trials of mTOR inhibitors for diffuse arteriopathy of children with SVAS or WS, it is prudent to Figure 6 . Rapamycin inhibits mammalian target of rapamycin (mTOR) signaling and proliferation of smooth muscle cell (SMC) from patients with supravalvular aortic stenosis (SVAS) and Williams syndrome (WS). A, Representative Western blotting for mTOR signaling effectors in coronary artery SMC from a patient with SVAS and a control age-matched individual in response to 20% FBS and rapamycin at 0 to 100 ng/mL for 24 hours. Phospho-p70-S6 kinase (S6K) and phospho-S6 normalized to β-actin for the patient with SVAS vs 3 controls are shown in the histograms. B, Similar analysis in ascending aorta SMC from a patient with WS vs 3 controls. C, Growth curves of coronary artery SMC from a patient with SVAS vs 4 controls plated at 2×10 4 cells/well in response to 20% FBS±rapamycin at 10 ng/mL for 0 to 8 days or treated with rapamycin at 0 to 100 ng/mL for 8 days (n=6-8 replicates from each subject, *P<0.05, **P<0.01, ***P<0.001, 1-way ANOVA). D, Similar analysis of ascending aorta SMC from a patient with WS vs 3 controls.
perform further investigations to both mitigate undesired effects and to assess whether the survival of experimental animals can be prolonged. To that end, we have embarked on a new study to determine for synergism of mTOR inhibitors with other classes of drugs that inhibit SMC proliferation and to use postweanling Eln −/− mice partially rescued by expression of a transgene for human ELN. 29 We conclude that mTOR inhibition by rapamycin is a promising strategy to reduce SMC proliferation and aortic obstruction attributable to elastin deficiency, but that improvement in therapeutic efficacy without significant somatic growth retardation should be sought before initiating clinical trials for obstructive arteriopathy in children with SVAS and WS. 
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